(page under construction)




Veniam - The Internet of moving things

Veniam, a spin-off of the University of Porto, IT and the University of Aveiro, has proven, in very practical terms, how knowledge derived from investment in science and technology can be transformed into products for global markets and qualified jobs in Portugal. At the forefront of the “Internet of Moving Things,” Veniam turns buses, cars, trucks and other vehicles into Wi-Fi hotspots, capable of expanding Internet connectivity to all citizens. Veniam helps to improve the quality of transport fleet services and the operational efficiency of controlled industrial sites, such as ports, airports, mines, plants, etc., through cloud-managed services. The concept was tested in Porto, where Veniam is based and operates the world’s largest vehicle Wi-Fi network, which includes STCP’s entire fleet. The company has already provided 4 million Internet sessions to more than 400,000 users. From UPTEC, and after signing an intellectual property agreement through U.Porto, Veniam has entered international markets and achieved significant results in Singapore and New York. João Barros, alumni and Professor of the University of Porto and CEO of Veniam says that "it is a great privilege to be able to lead this project and work with an extraordinary team." Veniam has recently received an investment of €22 million through Series B Financing, raising the total amount of risk capital invested in the company to €26 million.

For more information on Veniam technologies, click here.



Immunethep - For a safe tomorrow

"Results can, sometimes, take several years to achieve and they are the product of the work of many people," says Bruno Santos, CEO of Immunethep. On 25 June 2014, after many years of research and an intensive project of applied research (carried out since 2012), Pedro Madureira and the Venture Catalysts signed a licensing agreement between U. Porto and Immunethep. This event marked the beginning of a new U. Porto spin-off biotech start-up that, since its creation, grasped the full extent of the path that lay ahead to transform research results into something with a high impact on the health and lives of millions of people. Immunethep was ready to start the first phase of clinical trials (beginning of 2017), after having carried out preclinical trials since 2015, with its PNV1 vaccine. The PNV1 is the first effective vaccine to prevent infections caused by all serotypes of a group of bacteria, including multi-resistant bacteria, and is intended to cover the entire population, from newborns to the elderly. This vaccine was based on the discovery of an immunosuppression mechanism shared by different bacteria, such as Staphylococcus Aureus, Streptococcus Pneumoniae, Klebsiella Pneumoniae, Escherichia Coli and Group B Streptococcus, which are some of the most dangerous bacteria, responsible for severe morbidity and mortality.
“All our research work and line of products are developed to answer medical needs that still don’t have practical solutions,” says Pedro Madureira, CSO of Immunethep. The company is strongly focused on developing effective immunotherapies to fight infections caused by multi-resistant bacteria, which is the case of the PNV1 vaccine.

For more information on the vaccine licensed to Immunethep, click here.